Free tool
FAERS Monitor: Evomela
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207155 or its brand name (Evomela, Melphalan Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
22,969
Serious
22,377
97% of reports
Hospitalization
6,655
Death reported
5,247
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,484
- drug ineffective1,400
- plasma cell myeloma1,286
- febrile neutropenia1,255
- mucosal inflammation1,148
- neutropenia1,124
- pyrexia1,071
- pneumonia1,066
- thrombocytopenia1,048
- diarrhoea1,016
- product use in unapproved indication929
- sepsis809
- disease progression782
- infection718
- neuropathy peripheral699
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 156 |
| 2005 | 324 |
| 2006 | 216 |
| 2007 | 211 |
| 2008 | 320 |
| 2009 | 369 |
| 2010 | 181 |
| 2011 | 531 |
| 2012 | 458 |
| 2013 | 772 |
| 2014 | 898 |
| 2015 | 1,161 |
| 2016 | 1,184 |
| 2017 | 1,236 |
| 2018 | 1,681 |
| 2019 | 1,868 |
| 2020 | 1,937 |
| 2021 | 1,961 |
| 2022 | 1,538 |
| 2023 | 1,964 |
| 2024 | 1,736 |
| 2025 | 1,262 |
| 2026 | 1,005 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,031,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mucosal inflammationSignal | 1,148 | 41.9 | 39.6 | 43,892 |
| plasma cell myelomaSignal | 1,286 | 31.2 | 29.5 | 36,364 |
| febrile neutropeniaSignal | 1,255 | 17.6 | 16.7 | 19,371 |
| thrombocytopeniaSignal | 1,048 | 8.7 | 8.2 | 7,057 |
| neutropeniaSignal | 1,124 | 7.6 | 7.2 | 6,451 |
| neuropathy peripheralSignal | 699 | 6.8 | 6.3 | 3,423 |
| sepsisSignal | 809 | 6.7 | 6.2 | 3,896 |
| disease progressionSignal | 782 | 6.1 | 5.7 | 3,315 |
| infectionSignal | 718 | 4.6 | 4.2 | 1,996 |
| product use in unapproved indicationSignal | 929 | 3.4 | 3.2 | 1,620 |
| pneumoniaSignal | 1,066 | 3.0 | 2.8 | 1,458 |
| pyrexiaSignal | 1,071 | 2.8 | 2.7 | 1,292 |
| off label useSignal | 2,484 | 2.6 | 2.5 | 2,548 |
| diarrhoea | 1,016 | 1.4 | 1.4 | 141 |
| drug ineffective | 1,400 | 1.0 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.